Sharemaestro Newsreel

Charles River Laboratories stock hits 52-week high at $285.13 By Investing.com

Charles River Laboratories International Inc. (CRL) stock has reached a 52-week high of $285.13, reflecting an 83.28% increase over the past year and a 41.4% year-to-date return. This surge follows strong second-quarter earnings that surpassed analyst expectations and led to increased price targets from …

Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Wednesday, Aug. 5, 2026 at 9:00 a.m. ET CALL PARTICIPANTS Vice President of Investor Relations - Todd Spencer Chief Executive Officer - Birgit Girshick Executive Vice President and Chief Financial Officer - Glenn Coleman Full Conference Call Transcript …

IQV Stock Gains 42% in 3 Months: Here's What You Should Know

IQVIA (IQV) stock has gained 41.5% in the last three months, outperforming its industry and the S&P 500. This growth is attributed to record net bookings, a solid backlog in its R&D solutions, and an uplifted 2026 financial outlook. The company's shareholder-friendly actions, including …

Executive Dumps Over 14,000 Shares of Biotech Stock, Valued at $2.3 Million

Ian T. Clark, a Director at Guardant Health, Inc. (NASDAQ:GH), reported a sale of 14,180 shares of common stock on Aug. 4, 2026, according to a recent SEC Form 4 filing. Transaction summary Metric Value Transaction value $2.3 million Shares sold (indirectly held) 14,180 …

Thermo Fisher Completes $1.075B Sale of Microbiology Business to Astorg

Thermo Fisher Scientific has finalized the sale of its microbiology business to Astorg for approximately $1.075 billion, which includes cash and a $50 million seller note. This divestiture separates a $645 million-revenue operation from Thermo Fisher's Specialty Diagnostics segment, allowing Astorg to gain control …

TNDM Q2 Loss Narrower Than Expected, Revenues Miss, Stock Up

Tandem Diabetes Care (TNDM) reported a Q2 2026 loss of 31 cents per share, which was narrower than expected, though worldwide revenues of $254.6 million missed consensus estimates. Despite the revenue miss, the company's shares rose 19.1% after the announcement, driven by increased pump …

FDA Grants Breakthrough Device Designation to Freenome’s Blood-Based SimpleScreen™ Lung Cancer Screening Test

Freenome has received FDA Breakthrough Device Designation for its investigational blood-based SimpleScreen™ Lung cancer screening test. This AI-powered multiomic test is designed for high-risk adults aged 50-80 who are not currently undergoing guideline-recommended lung cancer screening. The designation aims to accelerate the development and …

NTRA Maintained by Guggenheim -- Price Target Raised to $360

Guggenheim has reiterated its Buy rating for Natera (NTRA) and increased its price target from $290 to $360, signaling strong confidence in the company's future. Despite this positive analyst outlook and Natera's high GF Score™ of 77/100, indicating strong growth and momentum, the stock …

Here's How Much a $1000 Investment in Medpace Made 10 Years Ago Would Be Worth Today

This article analyzes the hypothetical return on a $1000 investment in Medpace (MEDP) made ten years ago, calculating its current value to be $21,788.41, representing a 2,078.84% gain. It also provides an in-depth look at Medpace's business operations, financial performance, and future outlook, noting …

Astorg Completes Acquisition of Microbiology Business From Thermo Fisher Scientific, Establishing an Independent Global Diagnostics Specialist

The transaction establishes an independent company, with the Microbiology business providing the foundation of a global microbiology diagnostics platform serving the clinical, food safety and pharmaceutical markets. The investment reflects Astorg's focused healthcare strategy and distinctive approach to complex transactions, combining deep sector expertise, …

Thermo Fisher Scientific Completes Sale of its Microbiology Business to Astorg

WALTHAM, Mass., August 12, 2026--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that it has completed the sale of its microbiology business to Astorg, a leading pan-European private equity firm, forconsideration of approximately $1.075 billion, consisting of …

Morgan Stanley Adjusts Agilent Technologies PT to $175 From $160, Maintains Overweight Rating

Morgan Stanley has increased its price target for Agilent Technologies (A) to $175, up from $160, while reiterating an Overweight rating on the stock. This adjustment reflects a positive outlook for the company's financial performance and market position.

Natera Inc (NTRA) weekly advance accelerates with a 72.8% 12-week climb

The diagnostics stock closed at 322.10 USD as its weekly setup stayed active, with turnover running above its recent average.

Following Hamamatsu's Rebranding of NKT Photonics to Drive Laser Innovation, New Biophotonics Market Overview Maps Strategic Growth Through 2030

Company Logo Accelerating momentum across major industry heavyweights—highlighted by Thermo Fisher Scientific's Q2 2026 revenue beat, Hamamatsu Photonics' launch of its dedicated Lasers & Fibers Business Unit, and BD's $4.98 billion Q3 performance—is driving rapid adoption of optical diagnostic and imaging solutions worldwide. This …

Natera partners with Kupando for phase 1 cancer trial in Germany

Natera Inc. has announced a collaboration with Kupando Therapeutics for a Phase 1 clinical trial in Germany for KUP-101, an investigational immunotherapy for advanced tumors. Natera's Latitude tissue-free assay will be used to monitor treatment response by assessing circulating tumor DNA dynamics. The trial …

Medpace Holdings, Inc. $MEDP is Wasatch Advisors LP's 5th Largest Position

Wasatch Advisors LP has reduced its stake in Medpace Holdings, Inc. (MEDP) by 17.7%, but it still remains their fifth-largest holding, representing 2.2% of their portfolio. Despite the firm's strong quarterly earnings, analysts maintain a cautious "Hold" rating with an average price target below …

Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers

Phase I trial in Germany will support treatment response monitoring for Kupando Therapeutics' investigational immunotherapy using Latitude MRD testing AUSTIN, Texas, August 12, 2026--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new collaboration regarding a …

Baron Discovery Fund Gains from Strategic Accumulation of CareDx (CDNA)

The Baron Discovery Fund increased its position in CareDx (CDNA) after shares declined in Q3 2025 due to a draft local coverage decision by CMS that threatened reimbursement for its diagnostic tests. The fund believed the stock was undervalued at $11-12, representing a worst-case …

Goldman Sachs Discloses 2.63% Voting Interest in Qiagen via AFM Filing

Goldman Sachs Group Inc. has disclosed a 2.63% voting interest in Qiagen N.V., a Netherlands-based life sciences company, through a filing with the Dutch Authority for the Financial Markets. This stake is composed of both indirect real holdings and potential positions via various derivative …

First Patient Dosed as Trial Tests Immunotherapy in Skin Cancers

Natera, a leader in cell-free DNA, is collaborating with Kupando Therapeutics on a Phase 1 clinical trial for KUP-101, an immunotherapy for advanced skin cancers. Natera's Latitude MRD test will monitor treatment response by assessing ctDNA dynamics. The first patient has been dosed, and …

Labcorp (LH) Stock Looks About Right On Raised Full Year Guidance

Labcorp (LH) stock appears to be fairly valued according to Discounted Cash Flow and P/E ratio analyses, following a 54.1% increase over the last three years and a recent raise in full-year guidance. The intrinsic value estimate is close to the current share price, …

Charles River Laboratories International, Inc. $CRL Shares Sold by Pacer Advisors Inc.

Pacer Advisors Inc. significantly reduced its stake in Charles River Laboratories International (NYSE: CRL) by 98.4% in the first quarter, selling over 151,000 shares. Despite this, analyst sentiment remains largely positive, with a consensus "Moderate Buy" rating and a $255.65 average price target. The …

Idexx Laboratories (IDXX) Receives a Buy from Barclays

Renaissance Technologies LLC Acquires New Shares in NeoGenomics, Inc. $NEO

Renaissance Technologies LLC has acquired 254,172 shares of NeoGenomics, Inc. (NASDAQ:NEO) worth approximately $1.89 million, increasing institutional ownership of the company to 98.5%. This comes as NeoGenomics exceeded Q1 earnings expectations with $0.05 EPS and $201.66 million in revenue, an 11.2% year-over-year increase. Analysts …

Stock futures little changed as traders await inflation report

[Wall Street-Street Sign] P_Wei/E+ via Getty Images Stock index futures were muted on Wednesday as traders turned their attention to a closely watched consumer inflation report that could offer fresh clues on the Federal Reserve's policy path. Dow futures (INDU [https://seekingalpha.com/symbol/INDU]) -0.01%, S&P 500 …

E. Ohman J or Asset Management AB Makes New Investment in Twist Bioscience Corporation $TWST

E. Ohman J or Asset Management AB has initiated a new position in Twist Bioscience Corporation, acquiring 8,287 shares valued at approximately $853,000. This investment comes as other major institutional investors, such as ARK Investment Management and Millennium Management, have also increased their holdings …

Amundi Sells 116,588 Shares of Veracyte, Inc. $VCYT

Amundi significantly reduced its stake in Veracyte, Inc. by selling 116,588 shares, a 90.6% decrease, though other institutional investors increased their holdings. Veracyte surpassed Q1 earnings and revenue estimates, reporting $0.54 EPS and $150.32 million in revenue, leading analysts to maintain a "Moderate Buy" …

Labcorp Holdings Inc. (NYSE:LH) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Labcorp Holdings Inc. (NYSE:LH) has received a consensus "Moderate Buy" rating from twelve brokerages, with an average 12-month price target of $330.00. The company recently surpassed quarterly earnings expectations with $4.99 EPS and $3.73 billion in revenue, and declared a quarterly dividend of $0.72 …

Labcorp Holdings Inc. Stock 12‑Month Price Target Raised to $345.79, Implies 7% Upside

Labcorp Holdings Inc.'s average 12-month stock price target has increased to $345.79 from $340.73, based on estimates from 14 analysts. This updated target suggests a potential upside of approximately 7% from the August 11 closing price. The consensus rating for LH remains a "Buy" …

Did Stronger Guidance, Buybacks and New Oncology Tests Just Shift Labcorp Holdings' (LH) Investment Narrative?

In late July and early August 2026, Labcorp reported higher second-quarter and year-to-date earnings, raised its 2026 revenue growth guidance, completed a large share repurchase program, and expanded its precision oncology offering by making Roche's FDA-approved VENTANA PTEN (SP218) RxDx Assay available nationwide to …

IDEXX launches in-clinic cardiac test for cats and dogs

IDEXX Laboratories Inc. has launched the Catalyst proBNP Test, an in-clinic diagnostic tool for heart disease in cats and dogs. This test measures the NT-proBNP biomarker, providing rapid quantitative results to veterinarians for screening, diagnosis, and monitoring of cardiac conditions. The test will be …

Guardant Health CCO Chris Freeman sells $10.7m in common stock

Chris Freeman, CCO of Guardant Health (NASDAQ:GH), sold 63,605 shares of common stock for approximately $10.7 million on August 10, 2026, after exercising stock options. The sale occurred as the stock trades near its 52-week high, following a significant 200% gain over the past …

IDEXX Laboratories (IDXX) Unveils First Dual Species Cardiac Test For Dogs And Cats

3 Healthcare Stocks with Open Questions

3 Healthcare Stocks with Open Questions Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 22.3% gain over …

Technical Reactions to NEO Trends in Macro Strategies

This article provides a technical analysis of Neogenomics Inc. (NYSE: NEO) based on AI models, indicating strong sentiment across all time horizons and compelling upside potential. It outlines three distinct trading strategies (Position, Momentum Breakout, and Risk Hedging) with specific entry, target, and stop-loss …

Twist Bioscience (TWST) stake of 3.5% reported by William Blair Investment Management

William Blair Investment Management, LLC has reported a 3.5% beneficial ownership stake in Twist Bioscience Corp (TWST), totaling 2,174,594 shares. This filing, a Schedule 13G/A, indicates that the investment firm has sole voting power over 1,975,454 shares and sole dispositive power over all 2,174,594 …